With new FDA submission, Novo Nordisk aims to trumpet Tresiba's hypoglycemia edge

30th May 2017 Uncategorised 0

Novo Nordisk just took another step toward a potential kick-start for its newest basal insulin, Tresiba. The Danish drugmaker submitted data from its cardiovascular safety study, Devote, to the FDA, hoping to amp up its label to compete in a hotly contested segment of the diabetes market.

More: With new FDA submission, Novo Nordisk aims to trumpet Tresiba's hypoglycemia edge
Source: fierce